Investigational Site Number 826007

Manchester M239LT

0 studies enrolling now · 4 studies all time

What they study most

Hematopoietic Neoplasm, Hypercholesterolaemia, Hypercholesterolemia, Prostate Cancer

Studies at this site

• Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis — Completed
• Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin) — Completed
• Cabazitaxel at 20 mg/m² Compared to 25 mg/m² With Prednisone for the Treatment of Metastatic Castration Resistant Prostate Cancer — Completed
• Long-term Safety and Tolerability of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in High Cardiovascular Risk Patients With Hypercholesterolemia (ODYSSEY Long Term) — Completed